Genesis Molecular AI
The frontier AI for drug discovery, unifying foundation models and physics to reinvent medicine.
Last updated September 1, 2026
Overview
Genesis Molecular AI is a biotechnology company that pairs leading AI researchers and simulation experts with world-class drug hunters to optimize drug discovery and create new medicines. It develops AI research, an AI platform called GEMS, and drug discovery programs for its own pipeline and major pharma partners.
History
Genesis Molecular AI is a biotechnology company. It pairs leading AI researchers and simulation experts with world-class drug hunters to optimize drug discovery and create new medicines. The company is supported by world-leading AI and life science investors. In 2026, Incyte expanded its collaboration with Genesis, with Genesis receiving $120M upfront consideration and data for model training, and at least 5 additional targets.
- Incyte Partnership Expansion
Genesis receives $120M upfront consideration and data for model training. With strong results on initial programs, Incyte expanded the ongoing collaboration with at least 5 additional targets.
Products and positioning
GEMS
The AI operating system for molecular design.
Pearl
The Next Generation Foundation Model for Drug Discovery.
Flagship businesses
- GEMS: The AI operating system for molecular design
- Pearl: The Next Generation Foundation Model for Drug Discovery
Leadership
| Name | Title | Tenure |
|---|---|---|
| Evan Feinberg | executive | — |
| Sergey Edunov | executive | — |
| Shifeng Pan | executive | — |
| Will McCarthy | executive | — |
Sources
Cite this profile: Cite the canonical profile. /brand-wiki/genesis-molecular-ai · Editorial policy · How profiles are compiled